ReviewBiomedical reports2025
Herbal drug‑based nanotherapy for hepatocellular carcinoma: Quercetin‑contained nanocarrier as a multipurpose therapeutic agent against hepatocellular carcinoma (Review).
Review in Biomedical reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Nanocarrier-mediated targeting of NF-κB and JAK/STAT signaling pathways in hepatocellular carcinoma: mechanisms and therapeutic strategies.Journal of experimental & clinical cancer research : CR · 2026Review
- Dual-targeting phytochemicals Ergosterol and Quercetagetin implicate steroid metabolism-associated pathways in lung and liver cancer models.Frontiers in pharmacology · 2026Article
- Traditional Chinese Medicine Monomers and Their Derivatives as a Promising Therapeutic Tool for Hepatocellular Carcinoma by Activation of Mitophagy.Drug design, development and therapy · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer remains one of the leading causes of morbidity and mortality worldwide, with hepatocellular carcinoma (HCC) accounting for ~75% of all primary liver cancers and exhibiting a high incidence rate. Unfortunately, the response rate to chemotherapeutic agents for liver cancer is relatively low, primarily due to the development of drug resistance and the lack of targeted therapeutic agents. The present study focused on the anticancer mechanisms of quercetin and the development of innovative nanocarriers designed to enhance its efficacy against HCC while mitigating drug resistance. Quercetin demonstrates a diverse array of biological activities, making it a promising candidate for therapeutic applications. Its mechanisms include inhibition of tumor cell cycle, induction of apoptosis, modulation of reactive oxygen species and inhibition of chemotherapeutic resistance. Given these properties, extensive research has been conducted in pharmaceutical engineering to develop well-designed nanocarriers that incorporate quercetin. These nanocarriers aim to improve the bioavailability and targeting of quercetin, thereby enhancing its therapeutic efficacy against HCC and overcoming the challenges associated with anticancer drug resistance. Through this approach, quercetin could potentially play a pivotal role in the future of HCC treatment, providing a synergistic effect when combined with traditional chemotherapy leading to improved patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.